Nuclear Medicine

Uzm. Dr. Gündüzalp Buğrahan Babacan

Doctor and researcher Başakşehir Çam ve Sakura Şehir Hastanesi İstanbul
Thyroid NeoplasmsAdenocarcinomaStomach Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Thyroid Neoplasms 2 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Adenocarcinoma 2 publications
  • Stomach Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyNuclear Medicinesaglik.gov.trFrom source
  • InstitutionBaşakşehir Çam ve Sakura Şehir Hastanesisaglik.gov.trFrom source
  • Area of workThyroid NeoplasmsExtracted from 2 publications · Model version —From source
  • Publications21 publicationsOpenAlex, Europe PMC, ORCIDFrom source
  • ORCID0000-0002-0561-5739ORCIDFrom source
  • Last synchronised5 November 2026 10:37https://camsakurasehir.saglik.gov.tr/TR-1231581/gorev-yapan-hekimlerimiz.html#gunduzalp-bugrahan-babacansaglik.gov.tr

Scientific work

Publications on Thyroid Neoplasms

21 publications
Publications by year Most: 10, in 2025
  1. 2023: 3 publications
  2. 2024: 5 publications
  3. 2025: 10 publications
  4. 2026: 3 publications

  1. Prognostic value of PSMA PET–derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Imaging, 2026

    DOI 10.1186/s40644-026-01036-6 PMID 42063136 Open-access full textSource: OpenAlex

  2. Diffuse Gastric Uptake and Metabolic Superscan in the Patient with Multiple Myeloma

    Molecular imaging and radionuclide therapy, 2026

    DOI 10.4274/mirt.galenos.2026.43765 PMID 42334005 Open-access full textSource: Europe PMC

  3. Is Eligibility Enough? Pretreatment Prediction of Failure to Reach a Second Cycle of [177Lu]Lu-PSMA Radioligand Therapy

    Diagnostics, 2026

    DOI 10.3390/diagnostics16203359 PMID 42938199 Open-access full textSource: ORCID

  4. Novel heterogeneity method for predicting survival in non-metastatic triple-negative breast cancer

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2025

    DOI 10.1016/j.remnie.2025.500112 PMID 39921170 Source: ORCID

  5. Nuevo método de heterogeneidad para predecir la supervivencia en el cáncer de mama triple negativo no metastásico

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2025.500112 Source: ORCID

  6. The effect of digital PET/CT and reconstruction algorithms on semi-quantitative values and Deauville scoring in patients with lymphoma.

    PubMed, 2025

    DOI 10.1967/s002449912904 PMID 41389257 Source: OpenAlex

  7. Comparison of different response evaluation criteria in interim PET/CT for diffuse large B-cell lymphoma: is Δtotal metabolic tumor volume a worthwhile measure?

    Nuclear Medicine Communications, 2025

    DOI 10.1097/mnm.0000000000002047 PMID 40910350 Source: ORCID

  8. Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2024.500080 Source: ORCID

  9. Utilidad de la PET/TC con [18F]FDG más allá de la estadificación: importancia pronóstica de la sarcopenia y del metabolismo del tejido adiposo en el carcinoma esofágico

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2024.500090 Source: ORCID

  10. [18F]FDG PET/CT beyond staging: Prognostic significance of sarcopenia and adipose tissue metabolism in esophageal carcinomas

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2025

    DOI 10.1016/j.remnie.2024.500090 PMID 39732336 Source: ORCID

View all 21 publications